Additional file 7: Table S4. of Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
收藏DataCite Commons2024-12-13 更新2024-07-25 收录
下载链接：
https://springernature.figshare.com/articles/dataset/Additional_file_7_Table_S4_of_Axitinib_and_sorafenib_are_potent_in_tyrosine_kinase_inhibitor_resistant_chronic_myeloid_leukemia_cells/4377584
下载链接
链接失效反馈官方服务：
资源简介：
Anti-GAB2 IP of Imatinib, Axitinib and Sorafenib vs DMSO treated cells. SILAC ratios are normalized to GAB2. Only sites with localization probabilities greater 0.75 and Andromeda scores greater 40 are shown. PEP: posterior error probability. (XLSX 12 kb)
伊马替尼（Imatinib）、阿昔替尼（Axitinib）与索拉非尼（Sorafenib）处理组细胞相较于二甲基亚砜（DMSO）处理组细胞的抗GAB2免疫沉淀（Anti-GAB2 IP）实验。以GAB2为参照对细胞培养稳定同位素氨基酸标记（SILAC）比值进行标准化处理。仅展示定位概率大于0.75且Andromeda得分大于40的位点。PEP：后验错误概率（posterior error probability）。(XLSX 12 kb)
提供机构：
Figshare
创建时间：
2016-12-15
